The life sciences sector in the United Kingdom is encountering significant challenges as new reforms regarding the National Health Service (NHS) drug evaluation process come into effect. Johan Kahlstrom, the
Life Sciences
2Articles
Shares in Oxford Nanopore surged as the FTSE 250 gene-sequencing specialist reported stronger than expected sales for the first half of 2025. The company expects to post revenues of around
